Hetty Carraway, MD

Articles

Frontline Therapy for Patients With AML and FLT3 Alterations

February 7th 2023

Expert perspectives on the emergence of FLT3-targeted therapies and their role in the first-line setting of acute myeloid leukemia management.

Role of Intensive Chemotherapy in Young, Fit Patients With AML

February 7th 2023

Centering focus on first-line treatment modalities, panelists highlight the ongoing role of intensive chemotherapy in the management of AML.

Acute Myeloid Leukemia: Optimizing Risk Stratification

January 31st 2023

Expert oncologists reflect on risk stratification in acute myeloid leukemia and the process of categorizing patients into ‘fit’ versus ‘unfit’ subsets.

Molecular Biomarker Testing in Acute Myeloid Leukemia

January 31st 2023

In light of novel targeted agents made available to patients with AML, panelists consider the value of timely molecular testing in this setting.

Current Classifications of Acute Myeloid Leukemia

January 24th 2023

Expert perspectives on current classification strategies in acute myeloid leukemia and how these guidelines make use of molecular markers.

Overview of Acute Myeloid Leukemia

January 24th 2023

Opening their discussion on the management of acute myeloid leukemia (AML), expert oncologists provide an overview on the incidence, diagnosis, and stratification of patients.

Dr. Carraway on the Importance of Testing for Biomarkers in Patients with MDS and AML

June 23rd 2022

Hetty Carraway, MD, discusses the role of biomarker testing in patients with myelodysplastic syndromes and acute myeloid leukemia.

Dr. Carraway on Next-Generation Sequencing in AML

April 14th 2022

Hetty Carraway, MD, discusses important considerations for the future of acute myeloid leukemia regarding mutations and next-generation sequencing.

Dr. Carraway on Predisposition to Acute Myeloid Leukemia

October 11th 2018

Hetty Carraway, MD, oncologist, Cleveland Clinic, discusses predisposition to acute myeloid leukemia (AML).